Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

被引：0
|
作者：
Tribich, Samuel
Maurice, James
机构：
来源：
FRONTLINE GASTROENTEROLOGY | 2020年 / 11卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [41] A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis
    Renna, Sara
    Mocciaro, Filippo
    Ventimiglia, Marco
    Orlando, Rosalba
    Macaluso, Fabio Salvatore
    Cappello, Maria
    Fries, Walter
    Mendolaro, Marco
    Privitera, Antonino Carlo
    Ferracane, Concetta
    Pisana, Valentina
    Magnano, Antonio
    Pluchino, Dario
    Inserra, Gaetano
    Scarpulla, Giuseppe
    Garufi, Serena
    Carroccio, Antonio
    Siringo, Sebastiano
    Di Mitri, Roberto
    Cottone, Mario
    Orlando, Ambrogio
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (12) : 1292 - 1298
  • [42] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
    Albenberg, Lindsey G.
    Mamula, Petar
    Kelsen, Judith R.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
  • [43] Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update
    Burri, Emanuel
    Maillard, Michel H.
    Schoepfer, Alain M.
    Seibold, Frank
    Van Assche, Gert
    Riviere, Pauline
    Laharie, David
    Manz, Michael
    DIGESTION, 2020, 101 (SUPPL 1) : 2 - 15
  • [44] Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1
    Loftus, E. V.
    Sands, B. E.
    Colombel, J. -F.
    Dotan, I.
    Khalid, J. M.
    Tudor, D.
    Geransar, P.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S317 - S318
  • [45] Vedolizumab is superior than Adalimumab in Patients with Ulcerative colitis
    Di Lellis, Maddalena Angela
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01):
  • [46] SUSTAINED CORTICOSTEROID-FREE REMISSION WITH VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS OF GEMINI 1
    Loftus, Edward V.
    Sands, Bruce E.
    Colombel, Jean Frederic
    Dotan, Iris
    Khalid, Javaria M.
    Tudor, David
    Geransar, Parnia
    GASTROENTEROLOGY, 2018, 154 (06) : S390 - S390
  • [47] Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis
    Yang, Zheng
    Ye, Xiao-Qing
    Zhu, Yu-Zhen
    Liu, Zhou
    Zou, Ying
    Deng, Ying
    Guo, Can-Can
    Garg, Sushil Kumar
    Feng, Jin-Shan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 86 - 93
  • [48] Cost-effectiveness of immunomodulators versus infliximab for adults with moderate-to-severe ulcerative colitis.
    Malone, D.
    Hurwitz, J.
    Lofland, J.
    Nejadnik, B.
    Vanderpoel, J.
    Waters, H.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S53 - S54
  • [49] Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD
    Moens, A.
    Verstockt, B.
    Alsoud, D.
    Sabino, J.
    Ferrante, M.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S336 - S337
  • [50] Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany
    Sardesai, Aditya
    Dignass, Axel
    Quon, Peter
    Milev, Sandra
    Cappelleri, Joseph C.
    Kisser, Agnes
    Modesto, Irene
    Sharma, Puza P.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 279 - 290
12345